Magnetar Financial LLC Invests $1.58 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)

Magnetar Financial LLC bought a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 149,489 shares of the company’s stock, valued at approximately $1,576,000.

Several other large investors also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Roivant Sciences by 42.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after purchasing an additional 1,608 shares in the last quarter. VELA Investment Management LLC boosted its stake in Roivant Sciences by 8.8% in the fourth quarter. VELA Investment Management LLC now owns 32,386 shares of the company’s stock valued at $364,000 after buying an additional 2,621 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Roivant Sciences in the fourth quarter valued at about $36,000. Vanguard Personalized Indexing Management LLC boosted its stake in Roivant Sciences by 26.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company’s stock valued at $210,000 after buying an additional 3,955 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its stake in Roivant Sciences by 35.1% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 17,155 shares of the company’s stock valued at $193,000 after buying an additional 4,458 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Trading Up 0.6 %

ROIV traded up $0.06 during trading on Friday, hitting $10.80. The company’s stock had a trading volume of 3,579,769 shares, compared to its average volume of 4,771,108. The company has a quick ratio of 25.24, a current ratio of 25.24 and a debt-to-equity ratio of 0.07. Roivant Sciences Ltd. has a twelve month low of $8.24 and a twelve month high of $13.24. The stock’s fifty day moving average price is $10.86 and its 200-day moving average price is $10.88. The firm has a market capitalization of $7.98 billion, a P/E ratio of 2.13 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Thursday, May 30th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Roivant Sciences had a negative return on equity of 25.05% and a net margin of 3,484.86%. The company had revenue of $28.93 million for the quarter, compared to analyst estimates of $32.46 million. Analysts anticipate that Roivant Sciences Ltd. will post -1.12 EPS for the current year.

Analyst Upgrades and Downgrades

ROIV has been the topic of several research analyst reports. The Goldman Sachs Group raised their price objective on Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, June 18th. Deutsche Bank Aktiengesellschaft raised their price objective on Roivant Sciences from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Piper Sandler lifted their price target on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Friday, May 31st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.10.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.